Caris Life Sciences Q3 2026 Results: Net Income $15.2M, Down 37.3% YoY
Caris Life Sciences reported total revenue of $755.2 million for the nine months ended September 30, 2026, a significant increase from $519.1 million in the prior year period. The company achieved a net income from operations of $51.5 million for the first nine months of 2026, compared to an operating loss of $43.3 million in 2025, driven primarily by growth in molecular profiling services.
- Key figure
- Net income $15.2M · -37.3% YoY